BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roth BL, Kroeze WK. Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily. J Biol Chem 2015;290:19471-7. [PMID: 26100629 DOI: 10.1074/jbc.R115.654764] [Cited by in Crossref: 53] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Levit Kaplan A, Strachan RT, Braz JM, Craik V, Slocum S, Mangano T, Amabo V, O'Donnell H, Lak P, Basbaum AI, Roth BL, Shoichet BK. Structure-Based Design of a Chemical Probe Set for the 5-HT5A Serotonin Receptor. J Med Chem 2022. [PMID: 35195401 DOI: 10.1021/acs.jmedchem.1c02031] [Reference Citation Analysis]
2 Roth BL. Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs. Nat Struct Mol Biol 2019;26:535-44. [PMID: 31270468 DOI: 10.1038/s41594-019-0252-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
3 Roth BL, Irwin JJ, Shoichet BK. Discovery of new GPCR ligands to illuminate new biology. Nat Chem Biol 2017;13:1143-51. [PMID: 29045379 DOI: 10.1038/nchembio.2490] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
4 Chan JD, Grab T, Marchant JS. Kinetic profiling an abundantly expressed planarian serotonergic GPCR identifies bromocriptine as a perdurant antagonist. Int J Parasitol Drugs Drug Resist 2016;6:356-63. [PMID: 27397764 DOI: 10.1016/j.ijpddr.2016.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
5 Li F, Jiang X, Luo LL, Xu YM, Huang XX, Huang C, Zhang Y. A piggyBac-based TANGO GFP assay for high throughput screening of GPCR ligands in live cells. Cell Commun Signal 2019;17:49. [PMID: 31122241 DOI: 10.1186/s12964-019-0359-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Wold EA, Chen J, Cunningham KA, Zhou J. Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts. J Med Chem 2019;62:88-127. [PMID: 30106578 DOI: 10.1021/acs.jmedchem.8b00875] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
7 Wacker D, Stevens RC, Roth BL. How Ligands Illuminate GPCR Molecular Pharmacology. Cell 2017;170:414-27. [PMID: 28753422 DOI: 10.1016/j.cell.2017.07.009] [Cited by in Crossref: 253] [Cited by in F6Publishing: 224] [Article Influence: 50.6] [Reference Citation Analysis]
8 Sato S, Huang XP, Kroeze WK, Roth BL. Discovery and Characterization of Novel GPR39 Agonists Allosterically Modulated by Zinc. Mol Pharmacol 2016;90:726-37. [PMID: 27754899 DOI: 10.1124/mol.116.106112] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
9 Dohlman HG. Thematic Minireview Series: New Directions in G Protein-coupled Receptor Pharmacology. J Biol Chem 2015;290:19469-70. [PMID: 26126823 DOI: 10.1074/jbc.R115.675728] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
10 Drewry DH, Wells CI, Andrews DM, Angell R, Al-Ali H, Axtman AD, Capuzzi SJ, Elkins JM, Ettmayer P, Frederiksen M, Gileadi O, Gray N, Hooper A, Knapp S, Laufer S, Luecking U, Michaelides M, Müller S, Muratov E, Denny RA, Saikatendu KS, Treiber DK, Zuercher WJ, Willson TM. Progress towards a public chemogenomic set for protein kinases and a call for contributions. PLoS One 2017;12:e0181585. [PMID: 28767711 DOI: 10.1371/journal.pone.0181585] [Cited by in Crossref: 82] [Cited by in F6Publishing: 67] [Article Influence: 16.4] [Reference Citation Analysis]
11 Janero DR, Thakur GA. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target. Expert Opinion on Drug Discovery 2016;11:1223-37. [DOI: 10.1080/17460441.2016.1245289] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
12 Sloop KW, Briere DA, Emmerson PJ, Willard FS. Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases? ACS Pharmacol Transl Sci 2018;1:3-11. [PMID: 32219200 DOI: 10.1021/acsptsci.8b00009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
13 Oprea TI, Bologa CG, Brunak S, Campbell A, Gan GN, Gaulton A, Gomez SM, Guha R, Hersey A, Holmes J, Jadhav A, Jensen LJ, Johnson GL, Karlson A, Leach AR, Ma'ayan A, Malovannaya A, Mani S, Mathias SL, McManus MT, Meehan TF, von Mering C, Muthas D, Nguyen DT, Overington JP, Papadatos G, Qin J, Reich C, Roth BL, Schürer SC, Simeonov A, Sklar LA, Southall N, Tomita S, Tudose I, Ursu O, Vidovic D, Waller A, Westergaard D, Yang JJ, Zahoránszky-Köhalmi G. Unexplored therapeutic opportunities in the human genome. Nat Rev Drug Discov 2018;17:317-32. [PMID: 29472638 DOI: 10.1038/nrd.2018.14] [Cited by in Crossref: 133] [Cited by in F6Publishing: 107] [Article Influence: 33.3] [Reference Citation Analysis]
14 Khan MZ, He L. Neuro-psychopharmacological perspective of Orphan receptors of Rhodopsin (class A) family of G protein-coupled receptors. Psychopharmacology (Berl) 2017;234:1181-207. [PMID: 28289782 DOI: 10.1007/s00213-017-4586-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
15 Ehrlich AT, Maroteaux G, Robe A, Venteo L, Nasseef MT, van Kempen LC, Mechawar N, Turecki G, Darcq E, Kieffer BL. Expression map of 78 brain-expressed mouse orphan GPCRs provides a translational resource for neuropsychiatric research. Commun Biol 2018;1:102. [PMID: 30271982 DOI: 10.1038/s42003-018-0106-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
16 Barnash KD, James LI, Frye SV. Target class drug discovery. Nat Chem Biol 2017;13:1053-6. [PMID: 28926557 DOI: 10.1038/nchembio.2473] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
17 Di Pizio A, Behrens M, Krautwurst D. Beyond the Flavour: The Potential Druggability of Chemosensory G Protein-Coupled Receptors. Int J Mol Sci 2019;20:E1402. [PMID: 30897734 DOI: 10.3390/ijms20061402] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
18 Zhu S, Wu M, Huang Z, An J. Trends in application of advancing computational approaches in GPCR ligand discovery. Exp Biol Med (Maywood) 2021;246:1011-24. [PMID: 33641446 DOI: 10.1177/1535370221993422] [Reference Citation Analysis]
19 Bruchas MR, Roth BL. New Technologies for Elucidating Opioid Receptor Function. Trends Pharmacol Sci 2016;37:279-89. [PMID: 26833118 DOI: 10.1016/j.tips.2016.01.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
20 Mangini M, Iaccino E, Mosca MG, Mimmi S, D'Angelo R, Quinto I, Scala G, Mariggiò S. Peptide-guided targeting of GPR55 for anti-cancer therapy. Oncotarget 2017;8:5179-95. [PMID: 28029647 DOI: 10.18632/oncotarget.14121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
21 Purcell RH, Hall RA. Adhesion G Protein-Coupled Receptors as Drug Targets. Annu Rev Pharmacol Toxicol 2018;58:429-49. [PMID: 28968187 DOI: 10.1146/annurev-pharmtox-010617-052933] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 8.4] [Reference Citation Analysis]
22 Laschet C, Dupuis N, Hanson J. A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR-G protein interactions. J Biol Chem 2019;294:4079-90. [PMID: 30593506 DOI: 10.1074/jbc.RA118.006231] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
23 Chen Y, Sun H, Yao X, Yu Y, Tian T, Xu W, Zhou Y, Ouyang H. Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs. Cell Mol Life Sci 2021;78:8127-55. [PMID: 34783870 DOI: 10.1007/s00018-021-03983-8] [Reference Citation Analysis]
24 Kržan M, Vianello R, Maršavelski A, Repič M, Zakšek M, Kotnik K, Fijan E, Mavri J. The Quantum Nature of Drug-Receptor Interactions: Deuteration Changes Binding Affinities for Histamine Receptor Ligands. PLoS One 2016;11:e0154002. [PMID: 27159606 DOI: 10.1371/journal.pone.0154002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
25 Miller RE, Block JA, Malfait AM. What is new in pain modification in osteoarthritis? Rheumatology (Oxford) 2018;57:iv99-iv107. [PMID: 29361112 DOI: 10.1093/rheumatology/kex522] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
26 Dershem R, Metpally RPR, Jeffreys K, Krishnamurthy S, Smelser DT, Hershfinkel M, Carey DJ, Robishaw JD, Breitwieser GE; Regeneron Genetics Center. Rare-variant pathogenicity triage and inclusion of synonymous variants improves analysis of disease associations of orphan G protein-coupled receptors. J Biol Chem 2019;294:18109-21. [PMID: 31628190 DOI: 10.1074/jbc.RA119.009253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
27 Zou Y, Ewalt J, Ng HL. Recent Insights from Molecular Dynamics Simulations for G Protein-Coupled Receptor Drug Discovery. Int J Mol Sci 2019;20:E4237. [PMID: 31470676 DOI: 10.3390/ijms20174237] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
28 Foster SR, Hauser AS, Vedel L, Strachan RT, Huang XP, Gavin AC, Shah SD, Nayak AP, Haugaard-Kedström LM, Penn RB, Roth BL, Bräuner-Osborne H, Gloriam DE. Discovery of Human Signaling Systems: Pairing Peptides to G Protein-Coupled Receptors. Cell 2019;179:895-908.e21. [PMID: 31675498 DOI: 10.1016/j.cell.2019.10.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 20.5] [Reference Citation Analysis]
29 Sloop KW, Emmerson PJ, Statnick MA, Willard FS. The current state of GPCR-based drug discovery to treat metabolic disease. Br J Pharmacol 2018;175:4060-71. [PMID: 29394497 DOI: 10.1111/bph.14157] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
30 Andresen MC. Understanding diverse TRPV1 signaling - an update. F1000Res 2019;8:F1000 Faculty Rev-1978. [PMID: 31824648 DOI: 10.12688/f1000research.20795.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Morfa CJ, Bassoni D, Szabo A, McAnally D, Sharir H, Hood BL, Vasile S, Wehrman T, Lamerdin J, Smith LH. A Pharmacochaperone-Based High-Throughput Screening Assay for the Discovery of Chemical Probes of Orphan Receptors. Assay Drug Dev Technol 2018;16:384-96. [PMID: 30251873 DOI: 10.1089/adt.2018.868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Huang XP, Karpiak J, Kroeze WK, Zhu H, Chen X, Moy SS, Saddoris KA, Nikolova VD, Farrell MS, Wang S, Mangano TJ, Deshpande DA, Jiang A, Penn RB, Jin J, Koller BH, Kenakin T, Shoichet BK, Roth BL. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature 2015;527:477-83. [PMID: 26550826 DOI: 10.1038/nature15699] [Cited by in Crossref: 139] [Cited by in F6Publishing: 120] [Article Influence: 19.9] [Reference Citation Analysis]
33 Miller RE, Ishihara S, Bhattacharyya B, Delaney A, Menichella DM, Miller RJ, Malfait AM. Chemogenetic Inhibition of Pain Neurons in a Mouse Model of Osteoarthritis. Arthritis Rheumatol 2017;69:1429-39. [PMID: 28380690 DOI: 10.1002/art.40118] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
34 Paik YK, Lane L, Kawamura T, Chen YJ, Cho JY, LaBaer J, Yoo JS, Domont G, Corrales F, Omenn GS, Archakov A, Encarnación-Guevara S, Lui S, Salekdeh GH, Cho JY, Kim CY, Overall CM. Launching the C-HPP neXt-CP50 Pilot Project for Functional Characterization of Identified Proteins with No Known Function. J Proteome Res 2018;17:4042-50. [PMID: 30269496 DOI: 10.1021/acs.jproteome.8b00383] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
35 Kono M, Conlon EG, Lux SY, Yanagida K, Hla T, Proia RL. Bioluminescence imaging of G protein-coupled receptor activation in living mice. Nat Commun 2017;8:1163. [PMID: 29079828 DOI: 10.1038/s41467-017-01340-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
36 Geubelle P, Gilissen J, Dilly S, Poma L, Dupuis N, Laschet C, Abboud D, Inoue A, Jouret F, Pirotte B, Hanson J. Identification and pharmacological characterization of succinate receptor agonists. Br J Pharmacol 2017;174:796-808. [PMID: 28160606 DOI: 10.1111/bph.13738] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]